1 active not recruiting, 1 completed. 2 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Active not recruiting 1, Completed 1 |
| Phase 2 | 2 | Active not recruiting 1, Completed 1 |
Follow Pulmonary Neoplasms: new trials by email Literature Review of Pulmonary Neoplasms trials Research Report on Pulmonary Neoplasms
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation JDQ443, TNO155, tislelizumab - KRAS G12C Mutant Solid Tumors, Carcinoma, Non-Small-Cell Lung | Phase 1 / Phase 2 | Active not recruiting | Novartis Pharmaceuticals | 344 | 2021-02-24 | 2026-10-19 |
| RejuvenAir Lobectomy for Safety and Histology RejuvenAir - Lung Neoplasms, Pulmonary Neoplasms | Phase 1 / Phase 2 | Completed | CSA Medical, Inc. | 6 | 2015-08-01 | 2017-05-11 |
Lung Neoplasms (2) · Carcinoma, Non-Small-Cell Lung (1) · Colorectal Neoplasms (1) · Neoplasm Metastasis (1)
Lung Diseases (2) · Neoplasms (2) · Neoplasms by Site (2) · Respiratory Tract Diseases (2) · Respiratory Tract Neoplasms (2) · Thoracic Neoplasms (2) · Bronchial Neoplasms (1) · Carcinoma, Bronchogenic (1) · Colonic Diseases (1) · Digestive System Diseases (1) · Digestive System Neoplasms (1) · Gastrointestinal Diseases (1) · Gastrointestinal Neoplasms (1) · Intestinal Diseases (1) · Intestinal Neoplasms (1)
JDQ443 (1) · tislelizumab (1)
CSA Medical, Inc. (1) · Novartis Pharmaceuticals (1)
Canada (2) · Australia (1) · Belgium (1) · China (1) · Denmark (1) · France (1) · Germany (1) · Hong Kong (1) · Italy (1) · Japan (1) · Netherlands (1) · Singapore (1) · South Korea (1) · Spain (1) · Taiwan (1)